Bile acids modulate colonic MAdCAM-1 expression in a murine model of combined cholestasis and colitis.
ATP Binding Cassette Transporter, Subfamily B
/ genetics
Animals
Bile Acids and Salts
/ metabolism
Cell Adhesion Molecules
/ genetics
Cholangitis, Sclerosing
/ metabolism
Cholestasis
/ metabolism
Colitis
/ metabolism
Colon
/ metabolism
Dextran Sulfate
Disease Models, Animal
Disease Susceptibility
Humans
Inflammatory Bowel Diseases
/ metabolism
Mice
Mice, Knockout
Mucoproteins
/ genetics
Tumor Necrosis Factor-alpha
/ metabolism
Ursodeoxycholic Acid
/ metabolism
ATP-Binding Cassette Sub-Family B Member 4
Journal
Mucosal immunology
ISSN: 1935-3456
Titre abrégé: Mucosal Immunol
Pays: United States
ID NLM: 101299742
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
09
12
2019
accepted:
02
09
2020
pubmed:
3
10
2020
medline:
30
11
2021
entrez:
2
10
2020
Statut:
ppublish
Résumé
Primary sclerosing cholangitis (PSC) is a progressive fibrosing cholestatic liver disease that is strongly associated with inflammatory bowel disease (IBD). PSC-associated IBD (PSC-IBD) displays a unique phenotype characterized by right-side predominant colon inflammation and increased risk of colorectal cancer compared to non-PSC-IBD. The frequent association and unique phenotype of PSC-IBD suggest distinctive underlying disease mechanisms from other chronic liver diseases or IBD alone. Multidrug resistance protein 2 knockout (Mdr2
Identifiants
pubmed: 33004979
doi: 10.1038/s41385-020-00347-6
pii: S1933-0219(22)00147-7
pmc: PMC7954872
mid: NIHMS1629878
doi:
Substances chimiques
ATP Binding Cassette Transporter, Subfamily B
0
Bile Acids and Salts
0
Cell Adhesion Molecules
0
Madcam1 protein, mouse
0
Mucoproteins
0
Tumor Necrosis Factor-alpha
0
Ursodeoxycholic Acid
724L30Y2QR
Dextran Sulfate
9042-14-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
479-490Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK048520
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK050189
Pays : United States
Organisme : BLRD VA
ID : I01 BX002182
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK104713
Pays : United States
Organisme : NIDDK NIH HHS
ID : R37 DK050189
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK095491
Pays : United States
Références
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D. & Adams, D. H. Primary sclerosing cholangitis. Lancet 382, 1587–1599 (2013).
pubmed: 23810223
Loftus, E. V. Jr. et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54, 91–96 (2005).
pubmed: 15591511
pmcid: 1774346
Folseraas, T. et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J. Hepatol. 57, 366–375 (2012).
pubmed: 22521342
pmcid: 3399030
Aron, J. H. & Bowlus, C. L. The immunobiology of primary sclerosing cholangitis. Semin. Immunopathol. 31, 383–397 (2009).
pubmed: 19468733
pmcid: 2758173
Sabino, J. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut 65, 1681–1689 (2016).
pubmed: 27207975
pmcid: 5036217
Vaughn, B. P. et al. A pilot study of fecal bile acid and microbiota profiles in inflammatory bowel disease and primary sclerosing cholangitis. Clin. Exp. Gastroenterol. 12, 9–19 (2019).
pubmed: 30666146
pmcid: 6330977
Torres, J. et al. The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease. U. Eur. Gastroenterol. J. 6, 112–122 (2018).
Miethke, A. G. et al. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology 63, 512–523 (2016).
pubmed: 26172874
Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631–643 (2016).
pubmed: 27532829
Larusso, N. F. et al. PC.01.8 the aesop trial: a randomized, double-blind, placebo-controlled, phase 2 study of obeticholic acid in patients with primary sclerosing cholangitis. Digestive Liver Dis. 50, e67 (2018).
Tabibian, J. H. & Lindor, K. D. Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?). Hepatology 60, 785–788 (2014).
pubmed: 24752961
Feagan, B. G. et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369, 699–710 (2013).
pubmed: 23964932
Sandborn, W. J. et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N. Engl. J. Med. 369, 711–721 (2013).
pubmed: 23964933
Eksteen, B. et al. Gut homing receptors on CD8 T cells are retinoic acid dependent and not maintained by liver dendritic or stellate cells. Gastroenterology 137, 320–329 (2009).
pubmed: 19233184
pmcid: 3201985
Eksteen, B. et al. Hepatic endothelial CCL25 mediates the recruitment of CCR9+ gut-homing lymphocytes to the liver in primary sclerosing cholangitis. J. Exp. Med 200, 1511–1517 (2004).
pubmed: 15557349
pmcid: 2211943
Grant, A. J., Lalor, P. F., Hubscher, S. G., Briskin, M. & Adams, D. H. MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease). Hepatology 33, 1065–1072 (2001).
pubmed: 11343233
de Krijger, M., Wildenberg, M. E., de Jonge, W. J. & Ponsioen, C. Y. Return to sender: lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. J. Hepatol. 71, 603–615 (2019).
pubmed: 31108158
Smit, J. J. et al. Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75, 451–462 (1993).
pubmed: 8106172
Pollheimer, M. J., Trauner, M. & Fickert, P. Will we ever model PSC? - “it’s hard to be a PSC model!”. Clin. Res. Hepatol. Gastroenterol. 35, 792–804 (2011).
pubmed: 21703962
Fickert, P. et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 127, 261–274 (2004).
pubmed: 15236191
Jahnel, J. et al. Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. Liver Int. 29, 1316–1325 (2009).
pubmed: 19558576
Bamias, G., Clark, D. J. & Rivera-Nieves, J. Leukocyte traffic blockade as a therapeutic strategy in inflammatory bowel disease. Curr. Drug Targets 14, 1490–1500 (2013).
pubmed: 23621509
pmcid: 3779486
Bloom, S., Fleming, K. & Chapman, R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut 36, 604–609 (1995).
pubmed: 7537707
pmcid: 1382505
Fujino, S. et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52, 65–70 (2003).
pubmed: 12477762
pmcid: 1773503
Katt, J. et al. Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. Hepatology 58, 1084–1093 (2013).
pubmed: 23564624
Ward, J. B. J. et al. Ursodeoxycholic acid and lithocholic acid exert anti-inflammatory actions in the colon. Am. J. Physiol. Gastrointest. Liver Physiol. 312, G550–G558 (2017).
pubmed: 28360029
Poupon, R. E., Bonnand, A. M., Chretien, Y. & Poupon, R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology 29, 1668–1671 (1999).
pubmed: 10347106
Paumgartner, G. & Beuers, U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 36, 525–531 (2002).
pubmed: 12198643
Van Nieuwkerk, C. M. et al. Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene. Gastroenterology 111, 165–171 (1996).
pubmed: 8698195
Ando, T. et al. Inflammatory cytokines induce MAdCAM-1 in murine hepatic endothelial cells and mediate alpha-4 beta-7 integrin dependent lymphocyte endothelial adhesion in vitro. BMC Physiol. 7, 10 (2007).
pubmed: 17868448
pmcid: 2045088
Ogawa, H. et al. Mechanisms of MAdCAM-1 gene expression in human intestinal microvascular endothelial cells. Am. J. Physiol. Cell Physiol. 288, C272–C281 (2005).
pubmed: 15483224
Cullen, S. N. et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective. J. Hepatol. 48, 792–800 (2008).
pubmed: 18314215
Van den Bossche, L. et al. Ursodeoxycholic acid and its taurine- or glycine-conjugated species reduce colitogenic dysbiosis and equally suppress experimental colitis in mice. Appl. Environ. Microbiol. 83, e02766–16 (2017).
Singh, S., Khanna, S., Pardi, D. S., Loftus, E. V. Jr. & Talwalkar, J. A. Effect of ursodeoxycholic acid use on the risk of colorectal neoplasia in patients with primary sclerosing cholangitis and inflammatory bowel disease: a systematic review and meta-analysis. Inflamm. Bowel Dis. 19, 1631–1638 (2013).
pubmed: 23665966
Chiang, J. Y. Recent advances in understanding bile acid homeostasis. F1000Res 6, 2029 (2017).
pubmed: 29188025
pmcid: 5698910
Cai, S. Y. & Boyer, J. L. The role of inflammation in the mechanisms of bile acid-induced liver damage. Dig. Dis. 35, 232–234 (2017).
pubmed: 28249287
pmcid: 6051694
Gadaleta, R. M., Garcia-Irigoyen, O. & Moschetta, A. Bile acids and colon cancer: Is FXR the solution of the conundrum? Mol. Asp. Med. 56, 66–74 (2017).
Gadaleta, R. M. et al. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 60, 463–472 (2011).
pubmed: 21242261
Lindor, K. D. et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50, 808–814 (2009).
pubmed: 19585548
pmcid: 2758780
Batta, A. K. et al. Enrichment of the more hydrophilic bile acid ursodeoxycholic acid in the fecal water-soluble fraction after feeding to rats with colon polyps. Cancer Res 58, 1684–1687 (1998).
pubmed: 9563483
Kelly, O. B. et al. Ursodeoxycholic acid attenuates colonic epithelial secretory function. J. Physiol. 591, 2307–2318 (2013).
pubmed: 23507881
pmcid: 3650696
Golden, J. M. et al. Ursodeoxycholic acid protects against intestinal barrier breakdown by promoting enterocyte migration via EGFR- and COX-2-dependent mechanisms. Am. J. Physiol. Gastrointest. Liver Physiol. 315, G259–G271 (2018).
pubmed: 29672156
pmcid: 6139640
Kim, E. K., Cho, J. H., Kim, E. & Kim, Y. J. Ursodeoxycholic acid inhibits the proliferation of colon cancer cells by regulating oxidative stress and cancer stem-like cell growth. PLoS One 12, e0181183 (2017).
pubmed: 28708871
pmcid: 5510851
Colombo, C. et al. Effects of ursodeoxycholic acid therapy for liver disease associated with cystic fibrosis. J. Pediatr. 117, 482–489 (1990).
pubmed: 2391610
Vavassori, P., Mencarelli, A., Renga, B., Distrutti, E. & Fiorucci, S. The bile acid receptor FXR is a modulator of intestinal innate immunity. J. Immunol. 183, 6251–6261 (2009).
pubmed: 19864602
Guo, C. et al. Bile acids control inflammation and metabolic disorder through inhibition of NLRP3 inflammasome. Immunity 45, 802–816 (2016).
pubmed: 27692610
Duboc, H. et al. Connecting dysbiosis, bile-acid dysmetabolism and gut inflammation in inflammatory bowel diseases. Gut 62, 531–539 (2013).
pubmed: 22993202
Long, S. L., Gahan, C. G. M. & Joyce, S. A. Interactions between gut bacteria and bile in health and disease. Mol. Asp. Med. 56, 54–65 (2017).
Song, X. et al. Microbial bile acid metabolites modulate gut RORgamma(+) regulatory T cell homeostasis. Nature 577, 410–415 (2020).
pubmed: 31875848
Hang, S. et al. Bile acid metabolites control TH17 and Treg cell differentiation. Nature 576, 143–148 (2019).
pubmed: 31776512
pmcid: 6949019
Ghosh, S. & Panaccione, R. Anti-adhesion molecule therapy for inflammatory bowel disease. Ther. Adv. Gastroenterol. 3, 239–258 (2010).
McMurray, R. W. Adhesion molecules in autoimmune disease. Semin. Arthritis Rheum. 25, 215–233 (1996).
pubmed: 8834012
Rivera-Nieves, J., Gorfu, G. & Ley, K. Leukocyte adhesion molecules in animal models of inflammatory bowel disease. Inflamm. Bowel. Dis. 14, 1715–1735 (2008).
pubmed: 18523998
pmcid: 2733908
Borchers, A. T., Shimoda, S., Bowlus, C., Keen, C. L. & Gershwin, M. E. Lymphocyte recruitment and homing to the liver in primary biliary cirrhosis and primary sclerosing cholangitis. Semin. Immunopathol. 31, 309–322 (2009).
pubmed: 19533132
pmcid: 2758172
Briskin, M. J., McEvoy, L. M. & Butcher, E. C. MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1. Nature 363, 461–464 (1993).
pubmed: 8502297
Streeter, P. R., Berg, E. L., Rouse, B. T., Bargatze, R. F. & Butcher, E. C. A tissue-specific endothelial cell molecule involved in lymphocyte homing. Nature 331, 41–46 (1988).
pubmed: 3340147
Lynch, K. D. et al. Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Clin. Gastroenterol. Hepatol. 18, 179–187 (2019).
Steinacher, D., Claudel, T. & Trauner, M. Therapeutic mechanisms of bile acids and nor-ursodeoxycholic acid in non-alcoholic fatty liver disease. Dig. Dis. 35, 282–287 (2017).
pubmed: 28249257
Fickert, P. et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 130, 465–481 (2006).
pubmed: 16472600
Fickert, P. et al. norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. J. Hepatol. 67, 549–558 (2017).
pubmed: 28529147
Trauner, M., Fickert, P. & Wagner, M. MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis. 27, 77–98 (2007).
pubmed: 17295178
Pauli-Magnus, C. et al. BSEP and MDR3 haplotype structure in healthy Caucasians, primary biliary cirrhosis and primary sclerosing cholangitis. Hepatology 39, 779–791 (2004).
pubmed: 14999697
Degiorgio, D. et al. ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression. J. Gastroenterol. 51, 271–280 (2016).
pubmed: 26324191
Oude Elferink, R. P. & Paulusma, C. C. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). Pflug. Arch. 453, 601–610 (2007).
Hall, L. J. et al. Induction and activation of adaptive immune populations during acute and chronic phases of a murine model of experimental colitis. Dig. Dis. Sci. 56, 79–89 (2011).
pubmed: 20467900
Kiesler, P., Fuss, I. J. & Strober, W. Experimental models of inflammatory bowel diseases. Cell Mol. Gastroenterol. Hepatol. 1, 154–170 (2015).
pubmed: 26000334
pmcid: 4435576
Sarafian, M. H. et al. Bile acid profiling and quantification in biofluids using ultra-performance liquid chromatography tandem mass spectrometry. Anal. Chem. 87, 9662–9670 (2015).
pubmed: 26327313
Dieleman, L. A. et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114, 385–391 (1998).
pubmed: 9844047
pmcid: 1905133